Question 1 · Hard
A 64-year-old woman has IgA lambda myeloma. At diagnosis, SPEP showed a 28 g/L band in the beta region, typed as IgA lambda by immunofixation. After four cycles of a regimen that includes daratumumab, a therapeutic IgG1 kappa monoclonal antibody, the beta-region band has gone. A new faint band of about 1 g/L is now seen in the gamma region, and immunofixation types it as IgG kappa. She feels well, the serum free light chain ratio has returned to normal, and she has not had a stem cell transplant. All her samples are serum from fully clotted tubes. The new band most likely comes from:
- ADaratumumab, the therapeutic antibody itself
- BOligoclonal immune reconstitution bands
- CFibrinogen left in an unclotted sample
- DRelapse of her original myeloma clone
Show answerHide answer
Answer: A · Daratumumab, the therapeutic antibody itself
Daratumumab is a human IgG1 kappa monoclonal antibody, and at therapeutic concentrations it can appear on SPEP and immunofixation as a small IgG kappa band. Her own clone is IgA lambda, so a band with a different heavy and light chain cannot be a relapse of that clone, and the normal free light chain ratio supports a response. Immune reconstitution bands are usually several small bands after intensive therapy such as transplant, and fibrinogen does not react with anti-IgG or anti-kappa and is absent from properly clotted serum. A daratumumab-specific immunofixation reflex assay, in which an anti-daratumumab antibody shifts the drug's band, confirms the cause. Without this check, the drug band could wrongly prevent a complete response from being recorded.
- B: Reconstitution bands usually follow transplant and are often several, not one IgG kappa band during daratumumab.
- C: Fibrinogen does not type as IgG kappa and is absent from clotted serum.
- D: Her clone is IgA lambda, so a new IgG kappa band is not the original clone.